Skip to main content

Advertisement

SpringerLink
Log in

ASO Visual Abstract: Expanding Staging Criteria in T1–2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx

  • ASO Visual Abstract
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Funding

E.A.M. receives support as the Rob and Karen Hale Distinguished Chair in Surgical Oncology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Author notes

  1. Eric P. Winer MD

    Present address: Yale Cancer Center, New Haven, CT, USA

  2. Joseph A. Sparano MD

    Present address: Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA

Authors and Affiliations

  1. Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA

    Olga Kantor MD, MS, Tari A. King MD & Elizabeth A. Mittendorf MD, PhD

  2. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA

    Olga Kantor MD, MS, Harold J. Burstein MD, PhD, Tari A. King MD, Eric P. Winer MD & Elizabeth A. Mittendorf MD, PhD

  3. Harvard Medical School, Boston, MA, USA

    Olga Kantor MD, MS, Harold J. Burstein MD, PhD, Tari A. King MD, Eric P. Winer MD & Elizabeth A. Mittendorf MD, PhD

  4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Harold J. Burstein MD, PhD & Eric P. Winer MD

  5. Exact Sciences Corporation, Redwood City, CA, USA

    Steven Shak MD & Christy A. Russell MD

  6. Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Armando E. Giuliano MD

  7. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Gabriel N. Hortobagyi MD

  8. Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA

    Larissa A. Korde MD, MPH

  9. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

    Joseph A. Sparano MD

Authors
  1. Olga Kantor MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harold J. Burstein MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tari A. King MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steven Shak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christy A. Russell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Armando E. Giuliano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gabriel N. Hortobagyi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eric P. Winer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Larissa A. Korde MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Joseph A. Sparano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Elizabeth A. Mittendorf MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: O.K., L.A.K., J.S., and E.M. Formal analysis: O.K. Investigation: all authors. Methodology: O.K., H.J.B., T.A.K., G.N.H., E.P.W., L.A.K., J.A.S. Validation: all authors. Visualization: all authors. Writing, original draft: O.K., E.A.M. Writing, review and editing: all authors.

Corresponding author

Correspondence to Elizabeth A. Mittendorf MD, PhD.

Ethics declarations

Disclosure

E.A.M. reports compensated service on scientific advisory boards for AstraZeneca, Exact Sciences, Merck, and Roche/Genentech; uncompensated service on steering committees for Bristol Myers Squibb, Lilly, and Roche/Genentech; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. E.A.M. reports the following nonfinancial interests, nonremunerated activities: Board of Directors for the American Society of Clinical Oncology and Scientific Advisor for Susan G. Komen for the Cure Foundation. T.A.K. reports Speakers Honoraria and compensated service on scientific Advisory Board of Exact Sciences (formerly Genomic Health, Inc.) and compensated service for a Global Advisory Board of Besins Healthcare. C.A.R. and S.S. report employment by Exact Sciences (formerly Genomic Health, Inc.) and stock ownership of Exact Sciences. E.P.W. reports institutional research funding from Genentech/Roche; serving as a consultant for Athenex, Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, Gilead, GlaxoSmithKline, GSK, Jounce, Lilly, St. Lucia, Syros, and Zymeworks; a non-paid scientific advisory board membership at Leap Therapeutics; and serving as President-Elect of ASCO. All remaining authors have declared no conflicts of interest.

Ethics approval

Data were obtained with permission though the National Clinical Trials Network (NCTN) data archive. Secondary data use was approved by the Brigham and Women’s Institutional Review Board. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kantor, O., Burstein, H.J., King, T.A. et al. ASO Visual Abstract: Expanding Staging Criteria in T1–2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol 29, 8024–8025 (2022). https://doi.org/10.1245/s10434-022-12294-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12294-6

Search

Navigation